Peer AI and 4D Molecular Therapeutics: Why Most AI Pilots in Medical Writing Stall

Most pharmaceutical companies have launched AI pilots for medical writing. Few have moved beyond them. This webinar, presented by Peer AI in partnership with 4D Molecular Therapeutics, examines the structural reasons AI pilots stall in regulated writing environments, and what distinguishes the implementations that achieve sustained adoption. Drawing on cross-industry patterns, our presenters will walk through the most common failure modes: misalignment between AI capabilities and writer workflows, underestimating the role of institutional knowledge, over-indexing on speed metrics at the expense of quality and trust, and deploying tools that ask writers to change how they think rather than how they work. Viewers will leave with: A practical maturity framework for evaluating AI readiness in medical writing organizations A clear view of the organizational conditions that predict successful scale-up An understanding of why the transition from pilot to production depends more on change management than on technology selection Anita Modi, CEO/Co-Founder at Peer AI will be joined by Catherine Campbell, VP of Regulatory Affairs at 4D Molecular Therapeutics, for a conversation that bridges implementation strategy with real-world experience.